December 3, 2020
Business News

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19


VANCOUVER, British Columbia–()–AbCellera today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), was granted authorization by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Bamlanivimab, which has been shown in clinical trials to reduce viral load, symptoms, and hospitalizations, is authorized for the treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and who are at high risk of progressing to severe COVID-19 illness and/or hospitalization. Details regarding the…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Atlas Financial Holdings Files 2019 Annual Report on Form 10-K; Outlines Business Strategy as Technology-Focused Managing General Agent in Light Commercial Auto
Dahua USA Introduces New Cameras and Recorders Built on Industry-Leading Technologies
KBRA Releases ABS East 2020 Virtual Conference Recap